# Predictors of Response to Iron and Erythropoietin Stimulating Agents

Study · id `cardio:ct-nct03658876` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03658876](<https://clinicaltrials.gov/study/NCT03658876>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03658876

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 197 participants.

## Technical summary

Registry record NCT03658876. Randomized; no masking; primary purpose diagnostic. Start 2015-06-03 (actual); primary completion 2016-12-31 (actual). Results posted on 2019-07-05.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose diagnostic
- Phase: Phase 4
- Enrolled: 197 participants (enrolled count; ClinicalTrials.gov record NCT03658876, source copy `cardio:ctgov-nct03658876-2019-07-05`, retrieved 2026-10-26)
- Started: 2015-06-03 (actual) (ClinicalTrials.gov record NCT03658876, source copy `cardio:ctgov-nct03658876-2019-07-05`, retrieved 2026-10-26)
- Primary completion: 2016-12-31 (actual) (ClinicalTrials.gov record NCT03658876, source copy `cardio:ctgov-nct03658876-2019-07-05`, retrieved 2026-10-26)
- Completion: 2017-12-31 (actual) (ClinicalTrials.gov record NCT03658876, source copy `cardio:ctgov-nct03658876-2019-07-05`, retrieved 2026-10-26)
- Results first posted: 2019-07-05 (ClinicalTrials.gov record NCT03658876, source copy `cardio:ctgov-nct03658876-2019-07-05`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03658876-2019-07-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Predictors of Response to Iron and Erythropoietin Stimulating Agents
- Acronym: PRIME
- Condition: Renal Failure Chronic
- Condition: Anemia
- Intervention (Drug): Iron Sucrose Solution for Injection
- Intervention (Drug): Epoetin Beta
- Lead sponsor: Imperial College London
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Imperial College London (`cardio:org-imperial-college-london`)

## Provenance

Content hash: 6dce0ad2a2681e3336afcd782997d3f749df5530009d809a01bb0c9dba94d520
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
